362665-56-3

Basic information

• Product Name: Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-
• Synonyms: Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-;1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine;3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether;Tiprolisant;Tirolisant;Pitolisant (BF2.649)
• CAS NO: 362665-56-3
• Molecular Formula: C₁₇H₂₆ClNO
• Molecular Weight: 295.84744
• EINECS: -0
• Product Categories: API
• Mol File: 362665-56-3.mol

Chemical Properties

• Boiling Point: 398.7±32.0 °C(Predicted)
• Appearance: /
• Density: 1.056
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 9.41±0.10(Predicted)
• CAS DataBase Reference: Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-(362665-56-3)
• EPA Substance Registry System: Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-(362665-56-3)

Safety Data

• Hazardous Substances Data: 362665-56-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]is used as a therapeutic agent for the treatment of patients with narcolepsy, a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep, hypnagogic hallucinations, and sleep paralysis. As a selective inverse agonist at the histamine H3 receptor, Pitolisant modulates the activity of histamine neurons in the brain, leading to an increase in wakefulness and a reduction in sleepiness.
In addition to its primary use in narcolepsy treatment, Pitolisant may also have potential applications in other areas of medicine, such as the treatment of other sleep disorders, cognitive disorders, or even as an adjunct therapy for certain psychiatric conditions. However, further research and clinical trials are needed to fully explore and validate these potential applications.

Upstream product

• 110-89-4 piperidine 
• 61272-70-6 N-(3-bromopropyl)piperidine 
• 6282-88-8 3-(p-chlorophenyl)propanol 
• 1458-63-5 N-(3-chloropropyl)-piperidine 
• 462115-38-4 sodium 3-piperidinopropanolate 
• 61440-60-6 methanesulfonic acid 3-(4-chlorophenyl)-propyl ester 
• 104-58-5 3-piperidinopropan-1-ol 

Relevant articles and documents

1 - [3 - [3 - (4-chlorophenyl) propoxy] propyl]-piperidine hydrochloride method for the preparation of (by machine translation)

The invention relates to a 1 - [3 - [3 - (4-chlorophenyl) propoxy] propyl]-piperidine hydrochloride preparation method, the steps of : (1) the piperidine and 1,3-dihalogenated propane in the water-soluble polar non-protonic solvent, under the action of a basic compound, condensation reaction to obtain N-(3-halo-propyl) piperidine ; (2) N-(3- halogen propyl ) piperidine and 3 - (4-chlorophenyl) propyl alcohol in the solvent, under the action of an alkaline compound to ether, to obtain compound 1 - [3 - [3 - (4-chlorophenyl) propoxy] propyl]-piperidine ; (3) 1 - [3 - [3-4-chlorophenyl) propoxy] propyl]-piperidine and HCl reaction product is obtained. Process step of this invention is simple, the operation is convenient, easy availability of raw materials, the price is cheap, the product prepared in high yield, high purity, low cost, is suitable for industrial production. (by machine translation)

PROCESS FOR PREPARING 1-[3-[3-(4-CHLOROPHENYL)PROPOXY]PROPYL]-PIPERIDINE

The present invention relates to a process for preparing 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine (I) by reaction of 3-piperidinopropanol (II) with sodium hydride in an aprotic polar solvent and further reaction with 3- (4-chlorophenyl) propyl mesylate (III).

MONOHYDROCHLORIDE SALT OF 1- [3- [3- (4-CHLOROPHENYL) PROPOXY] PROPYL] -PIPERIDINE

New salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine. The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists

The reference compounds for histamine H3-receptor antagonists carry as a common feature an imidazole moiety substituted in the 4-position. Very recently novel ligands lacking an imidazole ring have been described possessing a N-containing non-aromatic heterocycle instead. In this study we investigated whether imidazole replacement, favourably by a piperidine moiety, is generally applicable to different structural classes of reference compounds, e.g., thioperamide, carboperamide, clobenpropit, FUB 181, ciproxifan, etc. While replacement led to a loss of affinity for many of the compounds, it was successfully applied to some ether derivatives. The piperidine analogues of FUB 181 and ciproxifan, 3-(4-chlorophenyl)propyl 3-piperidinopropyl ether hydrogen oxalate (6) and cyclopropyl 4-(3-piperidinopropyloxy)phenyl methanone hydrogen maleate (7), almost maintained in vitro affinities, pKi values of 7.8 and 8.4, respectively, and showed high potency in vivo after p.o. administration (ED50 values of 1.6 and 0.18 mg/kg, respectively).